BioSpace News Archive

Affygility Solutions, an occupational health and safety consulting firm for the life sciences industry, announced its expansion into Brazil.

ImmuneID, Inc., a precision immunology company employing a proprietary platform to identify and therapeutically target antibody interactions that drive immune diseases, today announced that Annalisa D’Andrea, Ph.D., has been appointed President and Chief Scientific Officer.

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the presentation of previously disclosed clinical results from the successful OTO-313 Phase 1/2 trial at the upcoming American Neurotology Society’s 56 th Annual Spring Meeting, which is part of the Combined Otolaryngology Spring Meeting (COSM), to be held virtually April 7-11, 2021.

Announcing a think tank-style meeting designed to develop actionable plans for schools to reopen and stay open [05-April-2021] BOSTON , April 5, 2021 /PRNewswire/ -- The Virus Project announced today that Meenta and their online marketplace for clinical testing, will be supporting the Back to Schools Conference April 12-14 th in Las Vegas that will bring to

Meniscus plays an important role in human knee and has various functions such as shock absorption, load transmission across the knee joint, and joint nutrition.

Pharmaceutical sterility testing is an investigation of the microorganisms. This sterility test conducted with help of fungistasis and bacteriostasis testing.

Synthetic biology market has evolved on the back of surging industry interest worldwide on the profound capabilities it is said to possess, mainly by virtue of redesigning biological components and systems.

Sick sinus syndrome is a common type of arrhythmia and is generally an indicator towards a set of signs and symptoms that can tell a doctor whether or not a patient’s sinoatrial node is functioning.

Bone regeneration refers to a well-orchestrated and complicated physiological process of bone formation.

FDA acknowledged that the preclinical safety data are acceptable to file an Investigational New Drug Application (IND) aimed at treating hospitalized COVID-19 patients at risk of developing ARDS